China Grand Pharmaceutical and Healthcare Holdings Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. More Details
Flawless balance sheet with solid track record.
Share Price & News
How has China Grand Pharmaceutical and Healthcare Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 512 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 512's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned 12.7% over the past year.
Return vs Market: 512 exceeded the Hong Kong Market which returned 21.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is China Grand Pharmaceutical and Healthcare Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StShareholders of China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Must Be Delighted With Their 455% Total Return
3 weeks ago | Simply Wall StIs China Grand Pharmaceutical and Healthcare Holdings Limited's (HKG:512) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Is China Grand Pharmaceutical and Healthcare Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 512 (HK$7.23) is trading below our estimate of fair value (HK$19.35)
Significantly Below Fair Value: 512 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 512 is poor value based on its PE Ratio (13.9x) compared to the Hong Kong Pharmaceuticals industry average (13.7x).
PE vs Market: 512 is poor value based on its PE Ratio (13.9x) compared to the Hong Kong market (11.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 512's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 512 is overvalued based on its PB Ratio (2.3x) compared to the HK Pharmaceuticals industry average (1.3x).
How is China Grand Pharmaceutical and Healthcare Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 512's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if 512's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 512's revenue (17.6% per year) is forecast to grow faster than the Hong Kong market (12.8% per year).
High Growth Revenue: 512's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 512's Return on Equity is forecast to be low in 3 years time (16%).
How has China Grand Pharmaceutical and Healthcare Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 512 has high quality earnings.
Growing Profit Margin: 512's current net profit margins (28.2%) are higher than last year (17.5%).
Past Earnings Growth Analysis
Earnings Trend: 512's earnings have grown significantly by 41.8% per year over the past 5 years.
Accelerating Growth: 512's earnings growth over the past year (55.6%) exceeds its 5-year average (41.8% per year).
Earnings vs Industry: 512 earnings growth over the past year (55.6%) exceeded the Pharmaceuticals industry 9.2%.
Return on Equity
High ROE: 512's Return on Equity (15.7%) is considered low.
How is China Grand Pharmaceutical and Healthcare Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 512's short term assets (HK$5.3B) exceed its short term liabilities (HK$4.3B).
Long Term Liabilities: 512's short term assets (HK$5.3B) exceed its long term liabilities (HK$1.3B).
Debt to Equity History and Analysis
Debt Level: 512's debt to equity ratio (21.4%) is considered satisfactory.
Reducing Debt: 512's debt to equity ratio has reduced from 213.7% to 21.4% over the past 5 years.
Debt Coverage: 512's debt is well covered by operating cash flow (60%).
Interest Coverage: 512's interest payments on its debt are well covered by EBIT (18.5x coverage).
What is China Grand Pharmaceutical and Healthcare Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 512's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.89%).
High Dividend: 512's dividend (1.52%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.03%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 512 has been paying a dividend for less than 10 years.
Growing Dividend: 512's dividend payments have increased, but the company has only paid a dividend for 2 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21.1%), 512's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Chao Zhou (30 yo)
Mr. Chao Zhou serves as Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited since April 2019 and serves as its Chief Executive Officer since June 01, 2021. Mr. Zhou serve...
Experienced Board: 512's board of directors are seasoned and experienced ( 11.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.
China Grand Pharmaceutical and Healthcare Holdings Limited's company bio, employee growth, exchange listings and data sources
- Name: China Grand Pharmaceutical and Healthcare Holdings Limited
- Ticker: 512
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$25.415b
- Shares outstanding: 3.55b
- Website: https://www.chinagrandpharm.com
Number of Employees
- China Grand Pharmaceutical and Healthcare Holdings Limited
- The Center
- Units 3302
- Hong Kong
China Grand Pharmaceutical and Healthcare Holdings Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 15:06|
|End of Day Share Price||2021/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.